ABIO - ARCA biopharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5030
+0.0030 (+0.60%)
At close: 3:35PM EST
Stock chart is not supported by your current browser
Previous Close0.5000
Open0.5220
Bid0.500 x 4000
Ask0.520 x 1000
Day's Range0.5002 - 0.5200
52 Week Range0.4500 - 1.9500
Volume47,668
Avg. Volume646,173
Market Cap7.004M
Beta (3Y Monthly)2.65
PE Ratio (TTM)N/A
EPS (TTM)-0.799
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update

    WESTMINSTER, Colo., Nov. 14, 2018 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.

  • GlobeNewswirelast month

    GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions

    AF detection by implanted Medtronic devicesSimilar trends for benefit in favor of Gencaro compared to active comparator for AF risk reduction observed by continuous monitoring.

  • GlobeNewswirelast month

    ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions

    Approximately 25% risk reduction for recurrence of AF seen in favor of Gencaro over active comparator as measured by AFB WESTMINSTER, Colo., Nov. 05, 2018 --  ARCA biopharma,.

  • Westminster biotech company receives second extension on delisting notice from Nasdaq
    American City Business Journals2 months ago

    Westminster biotech company receives second extension on delisting notice from Nasdaq

    ARCA Biopharma, a Westminster biotech company, has been given an additional 180 days to regain compliance with Nasdaq’s $1 per share minimum bid price requirement, according to an SEC form filed Tuesday. “Our Nasdaq listing is obviously very important to the company and our shareholders, so we are very focused on regaining compliance with the Nasdaq minimum closing bid price continued listing requirement,” Derek Cole, the company’s investor relations leader, said in an email. “The additional 180-day compliance period affords ARCA the opportunity to potentially regain compliance.” ARCA Biopharma is the 12th largest biotechnology/biosciences company in Colorado as ranked by number of employees, according to Denver Business Journal research.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 2, 2018 / U.S. equities were mixed on Monday after the U.S. and Canada agreed to revise the current North American Free Trade Agreement. The Dow Jones Industrial Average ...

  • GlobeNewswire3 months ago

    ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial

    ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA).  The request is part of the Company’s ongoing interaction with the FDA focused on the planned Phase 3 clinical development program of GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for heart failure (HF) patients at risk for atrial fibrillation (AF). The FDA’s SPA process is designed to facilitate the FDA’s review and approval of drugs by allowing FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product’s efficacy and safety.

  • ACCESSWIRE4 months ago

    Marijuana Stocks: Biotech Stock Report: 3 Companies To Watch In August 2018

    Last month, for instance, GT Biopharma (GTBP) announced a Material Transfer Agreement between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota. This Major Pharmaceutical Company will be supplying a formulation of their multibillion-dollar, widely prescribed oncology drug, which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.

  • ACCESSWIRE5 months ago

    3 Biotech Stocks in Focus on Tuesday

    CORAL GABLES, FL / ACCESSWIRE / July 31, 2018 / The Nasdaq iShares Biotechnology Index (IBB) has taken a turn toward ''greener pastures.'' The ETF rose by more than 1.2% on Tuesday as a number of biotech stocks moved higher in early morning trading. GT Biopharma (GTBP) is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary platforms. Earlier this month the company announced the addition of Dr. John N. Bonfiglio to GT Biopharma's Board of Directors.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma

    NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Biotech stocks Progenics and ARCA biopharma were both soaring on Monday. While ARCA had no news to explain its 40% climb, shares of Progenics soared higher after ...

  • ACCESSWIRE6 months ago

    Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks

    Research coverage has been initiated by WallStEquities.com on Aimmune Therapeutics Inc. (NASDAQ: AIMT), Alkermes PLC (NASDAQ: ALKS), Aratana Therapeutics Inc. (NASDAQ: PETX), and ARCA biopharma Inc. (NASDAQ: ABIO). The majority of Biotech companies research and develop products for the healthcare market.

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma

    NEW YORK, NY / ACCESSWIRE / May 11, 2018 / vTv Therapeutics and ARCA biopharma were both soaring in Thursday's trading session. Both had news as catalysts to drive shares higher with vTv Therapeutics announcing ...

  • ACCESSWIRE7 months ago

    Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want a free Stock Review on AIMT sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • ACCESSWIRE8 months ago

    Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease

    Stock Monitor: ARCA biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 03, 2018 / Active-Investors.com has just released a free research report on Insmed Inc. (NASDAQ: INSM ). If you want ...

  • SmarterAnalyst10 months ago

    Here’s Why Arca Biopharma Inc (ABIO) Shares Are Skyrocketing Today

    Case in point: Arca Biopharma Inc (NASDAQ:ABIO), whose shares are jumping 40% on Tuesday. Why? The drug maker announced positive results from its Phase 2B trial evaluating GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF). In all patients, Gencaro demonstrated a similar treatment benefit compared to the active control, metoprolol succinate (TOPROL-XL).

  • Market Exclusive10 months ago

    ARCA biopharma And ObsEva Just Put Out Clinical Trial Data

    ARCA biopharma, Inc. (NASDAQ:ABIO) has had a rough start to the week this week. The company put out a release detailing the progress of a phase II trial that was put in place to investigate an asset called Gencaro, which ARCA is trying to demonstrate can be a safe and effective treatment for atrial fibrillation […] The post ARCA biopharma And ObsEva Just Put Out Clinical Trial Data appeared first on Market Exclusive.

  • One Thing To Consider Before Buying ARCA biopharma Inc (NASDAQ:ABIO)
    Simply Wall St.11 months ago

    One Thing To Consider Before Buying ARCA biopharma Inc (NASDAQ:ABIO)

    If you are a shareholder in ARCA biopharma Inc’s (NASDAQ:ABIO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...